$CTKB News

Cytek Biosciences Says Jury Finds In Cytek’s Favor On Three Of Four Asserted Patent Claims; To Challenge Remaining Finding; Jury Awarded Past Damages Consisting Of $20M In Lost Profits And $36M In Royalties

Cytek Biosciences, Inc. Q2 2026 Earnings Call Summary

Cytek Biosciences, Inc. (CTKB) Q2 2026 Earnings Call Transcript

Cytek Biosciences, Inc. 2026 Q2 - Results - Earnings Call Presentation

Cytek Biosciences Inc (CTKB) (Q2 2026) Earnings Call Highlights: Revenue Up 6% to $48. ...

Cytek Biosciences Q2 Earnings Call Highlights

Cytek Biosciences, Inc. (CTKB) Reports Q2 Loss, Tops Revenue Estimates

Cytek Biosciences Reports Second Quarter 2026 Financial Results

Cytek Biosciences Q2 EPS $(0.09), Inline, Sales $48.140M Miss $48.610M Estimate

Cytek Biosciences Raises FY2026 Sales Guidance from $205.000M-$212.000M to $207.000M-$212.000M vs $208.767M Est

CSBR vs. CTKB: Which Life Sciences Stock Has Better Long-Term Upside?

Cytek Biosciences to Report Second Quarter 2026 Financial Results on August 5, 2026

Cytek® Biosciences Opens New Innovation Center in Bellevue to Advance R&D and Customer Engagement

Cytek Biosciences (CTKB) Stock Sees Fair Value Falls After Analysts Cut Targets

Cytek Biosciences, Inc. (CTKB) Presents at Singular Research's Las Vegas Invitational Conference - Slideshow

Cytek Biosciences to participate at the Singular Research’s Las Vegas Invitational Conference

Cytek Biosciences to Unveil Next-Generation Spectral Flow Cytometry Innovations at CYTO 2026

Stephens & Co. Maintains Overweight on Cytek Biosciences, Lowers Price Target to $4.75

Morgan Stanley Maintains Equal-Weight on Cytek Biosciences, Lowers Price Target to $5.5

Cytek Biosciences, Inc. 2026 Q1 - Results - Earnings Call Presentation